Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
September 10, 2020 16:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of...
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
September 10, 2020 16:00 ET
|
GW Pharmaceuticals plc
- Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy - Analysis of two...
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
September 10, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today...
GW Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress
August 06, 2020 16:00 ET
|
GW Pharmaceuticals plc
- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - - Conference call today at 4:30 p.m. EDT – ...
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
August 03, 2020 07:00 ET
|
GW Pharmaceuticals plc
– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine – ...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020
July 23, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
June 30, 2020 07:00 ET
|
GW Pharmaceuticals plc
- Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest...
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
June 23, 2020 19:01 ET
|
GW Pharmaceuticals plc
GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD) Burden on...
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity
June 04, 2020 16:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of...